Ahmad Awada, MD, PhD, Institute Jules Bordet, Brussels, Belgium, shares an update on the BrainStorm Program (NCT04109131), a clinical research platform which aims to optimize the treatment and management of patients with brain metastases. The study, which is performing MRIs and liquid biopsies and using cerebrospinal fluid (CSF) and circulating tumor DNA, aims to improve our understanding and prediction of the development of brain metastases, as well as enabling earlier diagnosis. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.